Searchable abstracts of presentations at key conferences in endocrinology

ea0011oc53 | Calcium and bone OC49 Novartis Oncology Young Investigator Award | ECE2006

Bone involvement in patients with adrenal incidentalomas: role of subclinical hypercortisolism

Chiodini I , Coletti F , Epaminonda P , Di Lembo S , Morelli V , Masserini B , Adda G , Arosio M

Previous studies suggest that in patients with adrenal incidentalomas (AI) subclinical hypercortisolism (SH) exerts a deleterious effect on bone mineral density (BMD), but scarce data are available about vertebral fractures. We evaluate BMD and prevalence of vertebral fractures in a sample of AI subjects with and without SH.Forty-seven consecutive AI inpatients were evaluated (17M, 30F). The patients were subdivided into two groups: with or without subcl...

ea0041ep145 | Calcium and Vitamin D metabolism | ECE2016

Bone mineral density measurement in newly diagnosed primary hyperparathyroidism patients

Tekin Bahar , Melin Uygur M. , Buket Bayram F. , Yavuz Dilek Gogas

Aim: Clinical presentation of primary hyperparathyroidism (PHPT) differs between populations. In this study, we aimed to examine bone mineral density (BMD) and bone metabolism parameters in newly diagnosed and untreated PHPT patients in a single endocrine center in İstanbul, Turkey.Methods: Consecutive 256 PHPT patients (50.7±14 years, F/M:205/51) and 89 healthy controls (38.8±10 years, F/M:67/22) were included in the study. Serum calcium...

ea0024p23 | (1) | BSPED2010

The impact of inflammatory bowel disease on pubertal growth is most marked in boys with Crohn’s disease

Mason A , Malik S , Russell R K , Bishop J , McGrogan P , Ahmed S F

Background: Puberty is understood to be commonly effected in adolescents with Crohn’s Disease (CD) and ulcerative colitis (UC). However, the extent of this effect and related problems with growth, have rarely been quantified.Objective: To determine the impact of CD and UC on pubertal growth.Methods: Retrospective study of 148 children with IBD (casenotes available, 135) who fulfilled the criteria for describing growth spurt pa...

ea0011p628 | Neuroendocrinology and behaviour | ECE2006

Sleep disorders in acromegaly: preliminary data demonstrating a high prevalence of restless leg syndrome (RLS)

Cannavo S , Condurso R , Squadrito S , Romanello G , Arico I , Mento G , Trimarchi F , Silvestri R

Sleep related breathing disorders (SRBD), due to bone mass and soft tissue swelling of the upper airways, are frequently reported by acromegalic patients, but sleep disorders other than SRBD were rarely studied in acromegaly. We evaluated 38 acromegalics (14 M, 24 F, age 52.8±2.3 yrs) by a structured interview for insomnia, excessive daytime sleepiness (EDS), SRBD, sleep related movement disorders (SRMD), circadian sleep disorders and parasomnias. Epworth sleepness scale ...

ea0026p505 | Bone/calcium/Vitamin D | ECE2011

Insulin sensitivity and bone mineral density in primary hyperparathyroidism

Gianotti L G , Tassone F T , Pellegrino M P , Cesario F C , Baffoni C B , Magro G M , Croce C G C , Borretta G B

Introduction: Recent data suggest a reciprocal influence between bone and energy metabolism. Mediators have been identified as osteocalcin (OC), which stimulates insulin (IRI) secretion and activity and IRI as bone anabolic factor. Primary hyperparathyroidism (PHPT) stimulates bone turnover, induces osteoporosis and is associated with increased IRI resistance. A positive relationship between OC and IRI sensitivity has been found in PHPT, but no data exist on the relationship b...

ea0029oc12.1 | Obesity Clinical | ICEECE2012

Circulating endocannabinoids are associated to cardiometabolic alterations independently from adiposity

Fanelli F. , Mezzullo M. , Belluomo I. , Di Lallo V. , Colavita M. , Baccini M. , Casadio E. , Ibarra Gasparini D. , Vicennati V. , Pasquali R. , Pagotto U.

Obesity is characterized by an increase of endocannabinoid circulating levels as anandamide (AEA) and 2-arachidonoyl-glycerol (2AG). Whether these lipids represent a biomarker of dysmetabolism or merely reflect the fat mass spill-over is still unclear. After generating rigorous, gender specific, plasma reference intervals by 2D-liquid chromatography-tandem mass spectrometry, we defined the 97.5thcentile of endocannabinoid distribution in the normal population as the cut-off ab...

ea0077op2.1 | Adrenal and Cardiovascular | SFEBES2021

A phase 1 clinical trial evaluating the safety and efficacy of up to two administrations of the adrenal PET tracer [18F]CETO in healthy volunteers and patients with primary aldosteronism

Senanayake Russell , Gillett Daniel , Bashari Waiel , MacFarlane James , Hu Lihua , Palma August , Aloj Luigi , Mendichovszky Iosif , Hader Stefan , Boros Istvan , Brown Morris , Cheow Heok , Aigbirhio Franklin , Gurnell Mark

Background: Primary aldosteronism (PA) is an important, potentially curable, cause of hypertension. Distinguishing unilateral and bilateral causes is a critical step in determining who should be considered for adrenalectomy. Adrenal vein sampling (AVS) remains the gold standard for lateralisation. However, AVS is technically challenging with limited availability. To address this, we have introduced molecular imaging using PET/CT with the radiotracer [11C]Metomidate ...

ea0086op2.1 | Adrenal and Cardiovascular | SFEBES2022

Novel radiolabeled ligand, Para-chloro-2-[18F]fluoroethyletomidate (CETO) compared to [11C]metomidate-PET (MTO) for the lateralisation of primary aldosteronism (PA)

Goodchild Emily , Senanayake Russell , Wu Xilin , Bashari Waiel , Salsbury Jackie , Argentesi Giulia , O'Toole Samuel , MacFarlane James , Laycock Kate , Gillett Dan , Boros Istvan , Aigbirhio Franklin , Sadhev Anju , Bird Nicholas , Hader Stefan , Warnes Victoria , Cruickshank Kennedy , Cheow Heok , Drake William , Gurnell Mark , Brown Morris

Introduction: Our MATCH study demonstrated 11-C ligand MTO was non-inferior to adrenal vein sampling in predicting surgical outcomes of adrenalectomy in patients with PA. The 20-min half-life of 11-C imposes logistic constraints. We investigated an 18-F ligand, CETO; its 2h half-life permits use in any facility with fluorodeoxyglucose (FDG)-positron emission tomography (PET) scan capability.Objective: To compare the detection of aldosterone-producing ade...

ea0026p523 | Bone/calcium/Vitamin D | ECE2011

Vitamin D and bone metabolism in adult patients with cystic fibrosis

Vuolo L , Carnovale V , Guerra E , Rubino M , Contaldi P , Rengo F , Colao A , Di Somma C

Objective: To evaluate Vitamin D levels and bone metabolism in adult patients with cystic fibrosis (CF).Patients and methods: One hundred patients with CF (53 F, 47 M; age 29±8 years). and 100 healthy controls were enrolled. Patients were assessed through clinical, and laboratory investigations. Evaluation of serum 25 hydroxy vitamin D (25OHD), vertebral fractures (quantitative morphometric analysis) and bone mineral density (BMD) at lumbar spine an...

ea0003p306 | Thyroid | BES2002

Plasma total and free tissue factor pathway inhibitor, tissue plasminogen activator antigen, and plasminogen activator inhibitor antigen levels in various thyriod disorders

Comlekci A , Ozcan M , Demirkan F , Sari I , Demir T , Ozsan H , Oruk G , Yesil S

Various abnormalities of coagulation may occur in patients with thyroid disorders and may range from subclinical laboratory abnormalities to clinically significant disturbances of coagulation. Tissue factor pathway inhibitor (TFPI) is a newly determined potent inhibitor of tissue factor dependent coagulation system. TFPI changes in various thyroid disorders has not been evaluated yet. In this study we have evaluated total TFPI (tTFPI), free TFPI (fTFPI), tissue plasminogen act...